Treatment of Metabolic Encephalopathy

Diagnosis and Initial Assessment

• The American Association for the Study of Liver Diseases recommends initial evaluation to include blood tests and brain imaging, preferably MRI, for patients with metabolic encephalopathy 1, 2
• Asterixis is strongly suggestive of metabolic encephalopathy, particularly in hepatic encephalopathy, according to the European Association for the Study of the Liver 1

Treatment Approach

1. Identify and Treat Underlying Cause

• Correction of the precipitating factor is paramount and can resolve nearly 90% of cases, especially in hepatic encephalopathy, as stated by the American Association for the Study of Liver Diseases 3, 4
• The European Association for the Study of the Liver recommends addressing common precipitating factors such as infections, electrolyte disturbances, hypoglycemia, and medication toxicity 2, 5

2. Specific Treatments Based on Etiology

For Hepatic Encephalopathy

• Lactulose is the first-line treatment for hepatic encephalopathy, according to the American Association for the Study of Liver Diseases, with an initial dosing of 25 mL every 1-2 hours until 2-3 soft bowel movements per day 3, 4
• Rifaximin is effective as an add-on therapy or alternative when lactulose is not tolerated, as recommended by the European Association for the Study of the Liver 3, 4

For Other Metabolic Encephalopathies

• Correcting specific metabolic derangements, such as phosphate, magnesium, and potassium supplementation, is crucial, as stated by the American Association for the Study of Liver Diseases 5
• Maintaining adequate glucose levels with continuous infusions if hypoglycemic is essential, according to the European Association for the Study of the Liver 5

3. Supportive Care

• Airway protection is critical, and patients with grade III/IV encephalopathy require intubation, as recommended by the American Association for the Study of Liver Diseases 6
• Positioning patients with head elevated at 30 degrees can help reduce intracranial pressure, according to the European Association for the Study of the Liver 6
• Fluid resuscitation and maintenance of adequate intravascular volume are vital, as stated by the American Association for the Study of Liver Diseases 5

4. Management of Complications

• For seizures, phenytoin is the preferred anticonvulsant in hepatic encephalopathy, according to the American Association for the Study of Liver Diseases 6
• For increased intracranial pressure, monitoring and management in an intensive care setting are necessary, as recommended by the European Association for the Study of the Liver 3, 4

Special Considerations

• Patients with higher grades of encephalopathy should be managed in an intensive care setting, as stated by the American Association for the Study of Liver Diseases 3, 4
• Recurrent intractable hepatic encephalopathy with liver failure is an indication for liver transplantation, according to the European Association for the Study of the Liver 3, 4

Metabolic Encephalopathy Diagnostic Approach and Management

Diagnostic Considerations

• A toxicology screen, including alcohol level and common drug intoxicants, is essential in the diagnostic workup of metabolic encephalopathy, as it can help identify potential causes of the condition, such as drug-induced or alcohol-related encephalopathy 7
• Lumbar puncture should be performed if infection cannot be excluded clinically, but only after ruling out increased intracranial pressure and coagulopathy, as recommended by the Infectious Diseases Society of America 8

Critical Differential Diagnoses

• The American Association for the Study of Liver Diseases recommends systematically ruling out diabetic emergencies, alcohol-related conditions, drug-induced encephalopathy, infections, electrolyte disorders, nonconvulsive status epilepticus, intracranial hemorrhage, and uremic encephalopathy, as these can mimic or coexist with metabolic encephalopathy 7

Nutritional Support

• The European Society for Clinical Nutrition and Metabolism recommends starting low-dose enteral nutrition once life-threatening metabolic derangements are controlled, independent of encephalopathy grade, with a protein intake of 1.5 g/kg/day 9
• The Society of Critical Care Medicine suggests delaying enteral nutrition only if shock is uncontrolled, active GI bleeding, or bowel ischemia is present 10

Management of Specific Conditions

• In patients with hepatic encephalopathy, the American College of Gastroenterology recommends maintaining adequate oxygenation and ventilation, targeting normal PaCO2, unless permissive hypercapnia is indicated, and monitoring arterial ammonia levels, especially in acute liver failure 9
• The American Society for Parenteral and Enteral Nutrition recommends not restricting protein intake in patients with hepatic encephalopathy, as this can worsen catabolism, and instead maintaining a protein intake of 1.5 g/kg/day 9

Management of Metabolic Encephalopathy

Initial Assessment and Treatment

• The American Association for the Study of Liver Diseases recommends immediate identification and correction of precipitating factors, which alone resolves nearly 90% of cases, combined with airway protection for severely altered patients and specific treatments based on the underlying etiology (hepatic, uremic, hypoxic, or toxic-metabolic) 11
• Brain imaging (preferably MRI, or CT if MRI unavailable) is mandatory to exclude structural lesions, intracranial hemorrhage, or other non-metabolic causes, as suggested by the European Association for the Study of the Liver 12

Specific Treatment Based on Etiology

• The American College of Gastroenterology recommends starting lactulose 25-45 mL (30 mL typical) orally or via nasogastric tube every 1-2 hours initially until bowel movement occurs, then adjust to 25 mL every 12 hours, for the treatment of hepatic encephalopathy 11
• The European Association for the Study of the Liver suggests adding rifaximin 550 mg orally twice daily if lactulose alone is insufficient or as add-on therapy for prevention of recurrence of hepatic encephalopathy 11

Supportive Care Measures

• The Society of Critical Care Medicine recommends avoiding benzodiazepines entirely as they precipitate or worsen hepatic encephalopathy, and instead using propofol or dexmedetomidine for sedation in intubated patients 11
• The American Association for the Study of Liver Diseases recommends noting that routine ammonia level testing is NOT recommended for diagnosis or monitoring of hepatic encephalopathy, though a normal ammonia level should prompt investigation for other etiologies 11

Special Considerations

• The American College of Gastroenterology recommends that patients with higher grades of encephalopathy (grade III/IV) require management in an intensive care unit with capability for intracranial pressure monitoring if needed 11
• The European Association for the Study of the Liver suggests that recurrent intractable hepatic encephalopathy with liver failure is an indication for liver transplantation evaluation 11

Post-Discharge Management

• The American Association for the Study of Liver Diseases recommends continuing maintenance lactulose therapy after episode resolves to prevent recurrence, and considering adding rifaximin 550 mg twice daily for patients with recurrent episodes 11
• The European Association for the Study of the Liver suggests educating patients and caregivers about medication effects (lactulose, rifaximin) and potential side effects like diarrhea, and teaching recognition of early signs of recurring encephalopathy 12

Management of Metabolic Encephalopathy

Initial Assessment and Diagnosis

• The European Association for the Study of the Liver recommends measuring plasma ammonia—a normal value brings the diagnosis of hepatic encephalopathy into question 13
• Patients with overt encephalopathy grade 3 and 4 (West Haven criteria) are at risk of aspiration and should be treated in the ICU, according to the Journal of Hepatology 13
• The American Association for the Study of Liver Diseases suggests using West Haven criteria for grading when at least temporal disorientation is present (grades ≥2) 13
• The American Association for the Study of Liver Diseases recommends adding Glasgow Coma Scale for patients with grades III-IV 13

Management of Precipitating Factors

• The American Gastroenterological Association recommends identification and management of precipitating factors: constipation, metabolic abnormalities (electrolytes, glucose), infection, or bleeding 14, 15, 16, 17
• The American Gastroenterological Association suggests continuous monitoring of underlying organ function (liver, kidney) and access to transplantation if needed 14, 15, 16, 17

Long-Term Management and Prevention

• The European Association for the Study of the Liver recommends lactulose as secondary prophylaxis following a first episode of overt hepatic encephalopathy 13
• The European Association for the Study of the Liver suggests considering adding rifaximin 550 mg twice daily for patients with recurrent episodes (>1 additional episode within 6 months of the first) 13
• The European Association for the Study of the Liver recommends a first episode of overt encephalopathy should prompt referral to a transplant center for evaluation 13
• The European Association for the Study of the Liver suggests patients with recurrent or persistent encephalopathy should be considered for liver transplantation 13